MRNA:OTCQB-Marina Biotech Inc (USD)

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 25.13

Change

+0.42 (+1.68)%

Market Cap

USD 0.02B

Volume

6.84M

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+12.95 (+2.71%)

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

+24.00 (+4.27%)

USD 69.68B
ARGX argenx NV ADR

+4.17 (+0.70%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

+4.00 (+1.72%)

USD 30.51B
ONC BeiGene, Ltd.

+23.55 (+10.27%)

USD 26.35B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

+2.13 (+8.45%)

USD 14.57B
INSM Insmed Inc

+1.73 (+2.49%)

USD 12.52B
INCY Incyte Corporation

+0.58 (+1.02%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

+2.85 (+4.86%)

USD 11.50B

ETFs Containing MRNA

MRN3:LSE Leverage Shares 3x Long M.. 300.22 % 0.00 %

+0.65 (+0.71%)

USD 0.66M
MSGR 6.26 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.70 % 0.00 %

+0.10 (+0.71%)

N/A
HVAX:CA 4.95 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 4.67 % 0.00 %

+0.11 (+0.71%)

N/A
CURG:LSE VanEck Genomics and Healt.. 3.64 % 0.00 %

+0.09 (+0.71%)

USD 4.76M
XNNV:XETRA Xtrackers MSCI Innovation.. 3.03 % 0.00 %

-0.18 (0.71%)

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

-0.09 (0.71%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

+0.25 (+0.71%)

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.69 % 0.00 %

+0.01 (+0.71%)

N/A
FCTR First Trust Lunt U.S. Fac.. 1.68 % 0.00 %

+0.81 (+0.71%)

N/A
TAEQ 1.46 % 0.00 %

N/A

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 4.72B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+4.53 (+0.71%)

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
LS:CA 0.00 % 2.21 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.14 (+0.71%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+0.71%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.13 (+0.71%)

N/A
RYH 0.00 % 0.40 %

N/A

N/A
XT iShares Exponential Techn.. 0.00 % 0.47 %

+1.23 (+0.71%)

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
MRNS:LSE -299.96 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.56% 35% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.56% 35% F 21% F
Trailing 12 Months  
Capital Gain -75.94% 24% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.94% 24% F 10% F
Trailing 5 Years  
Capital Gain -50.92% 62% D 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.92% 62% D 25% F
Average Annual (5 Year Horizon)  
Capital Gain 29.34% 73% C 83% B
Dividend Return 29.34% 73% C 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 140.10% 28% F 15% F
Risk Adjusted Return 20.94% 81% B- 57% F
Market Capitalization 0.02B 98% N/A 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector